@article {10518, title = {Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage.}, journal = {Nutrients}, volume = {9}, year = {2017}, month = {2017 Jun 06}, abstract = {

The purpose of this study is to determine if a preventive treatment with curcumin can protect intestinal epithelial cells from inflammatory damage induced by IFNγ. To achieve this goal we have used a human intestinal epithelial cell line (HT29) treated with IFNγ to undergo apoptotic changes that can reproduce the damage of intestinal epithelia exposed to inflammatory cytokines. In this model, we measured the effect of curcumin (curcuminoid from ) added as a pre-treatment at different time intervals before stimulation with IFNγ. Curcumin administration to HT29 culture before the inflammatory stimulus IFNγ reduced the cell apoptosis rate. This effect gradually declined with the reduction of the curcumin pre-incubation time. This anti-apoptotic action by curcumin pre-treatment was paralleled by a reduction of secreted IL7 in the HT29 culture media, while there was no relevant change in the other cytokine levels. Even though curcumin pre-administration did not impact the activation of the NF-κB pathway, a slight effect on the phosphorylation of proteins in this inflammatory signaling pathway was observed. In conclusion, curcumin pre-treatment can protect intestinal cells from inflammatory damage. These results can be the basis for studying the preventive role of curcumin in inflammatory bowel diseases.

}, keywords = {Anti-Inflammatory Agents, Non-Steroidal, Apoptosis, Cell Survival, Curcuma, Curcumin, Cytokines, Epithelial Cells, HT29 Cells, Humans, Inflammation, Interferon-gamma, Interleukin-7, Intestinal Mucosa, NF-kappa B, Phosphorylation, Signal Transduction}, issn = {2072-6643}, doi = {10.3390/nu9060578}, author = {Loganes, Claudia and Lega, Sara and Bramuzzo, Matteo and Vecchi Brumatti, Liza and Piscianz, Elisa and Valencic, Erica and Tommasini, Alberto and Marcuzzi, Annalisa} } @article {10567, title = {Intranasal Dexmedetomidine Sedation as Adjuvant Therapy in Acute Asthma Exacerbation With Marked Anxiety and Agitation.}, journal = {Ann Emerg Med}, volume = {69}, year = {2017}, month = {2017 01}, pages = {125-127}, abstract = {

We describe 2 patients with acute asthma exacerbation who were admitted to the emergency department (ED) with severe~agitation and restlessness as a prominent finding, for which bedside asthma treatment sedation with intranasal dexmedetomidine was performed. In both cases, dexmedetomidine allowed the patients to rest and improved tolerance to treatment. Dexmedetomidine is a unique sedative with an excellent safety profile and minimal effect on respiratory function. These properties render it particularly promising for the management of severe agitation in children admitted to the ED with acute asthma exacerbation.

}, keywords = {Acute Disease, Administration, Intranasal, Anxiety, Asthma, Child, Preschool, Dexmedetomidine, Emergency Service, Hospital, Female, Humans, Hypnotics and Sedatives, Infant, Psychomotor Agitation}, issn = {1097-6760}, doi = {10.1016/j.annemergmed.2016.08.005}, author = {Cozzi, Giorgio and Lega, Sara and Giorgi, Rita and Barbi, Egidio} } @article {7697, title = {Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study.}, journal = {Clin Res Hepatol Gastroenterol}, year = {2015}, month = {2015 Jun 29}, abstract = {

BACKGROUND AND OBJECTIVE: Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare disease of infancy, of possible autoimmune mechanism with poor prognosis due to its scarce response to immunosuppressive drugs. The aim of this retrospective multicenter study was to evaluate the efficacy and safety of intravenous immunoglobulin (IVIg) treatment in inducing and maintaining remission of the liver disease, in patients with GCH-AHA.

METHODS: Seven children with GCH-AHA, four newly diagnosed, and three in relapse, being treated with different therapies, received one to three IVIg infusions (0.5 to 2g/kg) in association with other immunosuppressive drugs. Subsequently five of them received monthly sequential IVIg infusions (mean 13.4, range 7-24).

RESULTS: IVIg infusions as first-line therapy associated with prednisone and other immunosuppressive drugs significantly (P=0.04) reduced the aminotransferase activity in all patients and normalized prothombin activity in the only patient with severe liver dysfunction. Sequential monthly IVIg infusions determined a steroid-sparing effect and allowed a complete or partial remission in all patients, although with temporary efficacy, since relapse of the hemolytic anemia and/or of liver disease occurred in all patients. IVIg infusions were associated with mild side effects in two patients.

CONCLUSIONS: IVIg infusion can be safely and effectively administered in patients with severe GCH-AHA at diagnosis, or in case of relapse, in association with other immunosuppressive drugs. Repeated IVIg infusions may help maintain remission, however, due to their temporary efficacy, they should not be routinely employed.

}, issn = {2210-741X}, doi = {10.1016/j.clinre.2015.03.009}, author = {Marsalli, Giulia and Nastasio, Silvia and Sciveres, Marco and Calvo, Pier Luigi and Ramenghi, Ugo and Gatti, Simona and Albano, Veronica and Lega, Sara and Ventura, Alessandro and Maggiore, Giuseppe} } @article {7777, title = {A young soccer player with sudden pain after kicking the ball.}, journal = {BMJ}, volume = {350}, year = {2015}, month = {2015}, pages = {h1944}, keywords = {Adolescent, Athletic Injuries, Emergency Medicine, Fractures, Bone, Humans, Ilium, Male, Soccer}, issn = {1756-1833}, doi = {10.1136/bmj.h1944}, author = {Lega, Sara and Rabach, Ingrid and Barbi, Egidio and Ventura, Alessandro} } @article {3607, title = {Acute-onset pretibial swelling.}, journal = {Indian Pediatr}, volume = {51}, year = {2014}, month = {2014 Apr}, pages = {334}, keywords = {Bone Marrow Diseases, Child, Preschool, Edema, Female, Granuloma Annulare, Humans, Leg, Tibia}, issn = {0974-7559}, author = {Lega, Sara and Rabusin, Marco and Pederiva, Federica} } @article {3519, title = {Severe neonatal hyperbilirubinemia and UGT1A1 promoter polymorphism.}, journal = {J Pediatr}, volume = {165}, year = {2014}, month = {2014 Jul}, pages = {42-5}, abstract = {

OBJECTIVE: To assess whether UGT1A1 promoter polymorphisms associated with Gilbert Syndrome (GS) occur with a greater frequency in neonates with severe hyperbilirubinemia.

STUDY DESIGN: In a case-control study performed at a single hospital center in Italy, 70 case subjects with severe hyperbilirubinemia (defined as bilirubin level >=20~mg/dL or 340~μmol/L) and 70 controls (bilirubin level <12~mg/dL or 210~μmol/L) were enrolled. Both case and control subjects were full term newborns. Polymerase chain reaction analysis on blood spot was performed to determine the frequency of UGTA1A1 promoter polymorphisms in cases and controls.

RESULTS: No statistical difference in the prevalence of UGTA1A1 gene variants was found between cases and controls (P~=~1). Thirteen infants homozygous for (TA)7 polymorphism associated with GS were in the case group (18.6\%) and 14 in the control group (20.0\%). A heterozygous group was also equally distributed between cases (44.3\%) and controls (42.9\%). No (TA)8 repeat was found in the 2 groups.

CONCLUSIONS: In our study population, GS polymorphism alone does not appear to play a major role in severe neonatal hyperbilirubinemia in neonates without signs of hemolysis.

}, keywords = {Case-Control Studies, Female, Genotype, Gilbert Disease, Glucuronosyltransferase, Humans, Hyperbilirubinemia, Neonatal, Infant, Newborn, Male, Polymerase Chain Reaction, Polymorphism, Genetic, Prevalence, Promoter Regions, Genetic}, issn = {1097-6833}, doi = {10.1016/j.jpeds.2014.03.013}, author = {Travan, Laura and Lega, Sara and Crovella, Sergio and Montico, Marcella and Panontin, Elisa and Demarini, Sergio} }